Exelixis has reached the enrollment target of 960 patients has been reached for COMET-1, the company’s Phase III trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of COMET-1 is overall survival. Exelixis expects top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014. COMET-1 is a randomized, double-blind, placebo-controlled trial designed to enroll  patients with mCRPC who have previously been treated w...